Takeda has posted phase 3 data on an autoimmune asset it acquired for $4 billion, laying down a marker ahead of a fight for market share with companies including Bristol Myers Squibb and Johnson & Johnson.
In December, Takeda reported two phase 3 trials of its TYK2 inhibitor, zasocitinib, in adults with moderate to severe plaque psoriasis met their primary endpoints. The Japanese drugmaker later t...
**Steelman:** Takeda’s zasocitinib data presents a compelling case for a highly effective oral psoriasis treatment, with superior efficacy to placebo and apremilast, and potential advantages over competitors like Sotyktu in both dosing convenience and response rates. The absence of food restrictions and once-daily dosing could enhance patient adherence, a critical factor in chronic disease management. Takeda’s revenue projections reflect confidence in zasocitinib’s market potential, backed by ro...